Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07680764 · ClinicalTrials.gov registry record · Phase 2
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07680764 is a Phase 2 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 160 participants.
The verdict
NCT07680764, a Phase 2 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
- DRUG Pumitamig
- DRUG Imzokitug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-08-15 |
| Est. Completion | 2030-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07680764
The ClinicalTrials.gov registry entry for NCT07680764 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pumitamig is the first listed.
NCT07680764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07680764 about?
NCT07680764 is a clinical study titled "A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
What is the current status of trial NCT07680764?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-08-15. Estimated completion is 2030-09-15.
What interventions are being tested in trial NCT07680764?
The interventions under investigation include: Pumitamig (DRUG), Imzokitug (DRUG).
Who is sponsoring clinical trial NCT07680764?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.